Company Information

CIN
Status
Date of Incorporation
13 August 2008
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
10,105,000
Authorised Capital
12,500,000

Directors

Sivaraman Mohan Mailatur
Sivaraman Mohan Mailatur
Director/Designated Partner
over 2 years ago
Bhaveshkumar Vallabhbhai Patel
Bhaveshkumar Vallabhbhai Patel
Director/Designated Partner
over 3 years ago
Himanshu Jayantbhai Shah
Himanshu Jayantbhai Shah
Director/Designated Partner
over 4 years ago
Rahul Gawande Sudhakar
Rahul Gawande Sudhakar
Director/Designated Partner
over 6 years ago
Meena Mohan
Meena Mohan
Director/Designated Partner
over 17 years ago

Past Directors

Hiren Dasharathbhai Patel
Hiren Dasharathbhai Patel
Additional Director
over 13 years ago
Melarkode Sankaraiyer Sivaraman
Melarkode Sankaraiyer Sivaraman
Director
over 17 years ago

Patents

Pharmacuetical Liquid Compositions Of Carfilzomib

ABSTRACT                                          70011451° The present invention provides a stable; ready to use, liquid composition comprising Carfilzomib or its pharmaceutically acceptable salt thereof, a stabilizing agent, a solubilizer, optionally a triglyceride, a tonicity contributing agent, having pH about ...

"Stable Liquid Compositions Of Daptomycin"

STABLE LIQUID COMPOSITIONS OF DAPTOMYCIN ABSTRACT A stable, aqueous liquid composition comprising, daptomycin or its acceptable salt thereof at a concentration of 26mg/mL or above, and other pharmaceutically acceptable excipients, wherein the composition is free of sugars.

Stable Liquid Compositions Of Melphalan

The present invention relates to a stable non-aqueous, ready to dilute liquid pharmaceutical composition comprising (i) melphalan or a pharmaceutically acceptable salt thereof and (ii) polyoxyethylene sorbitan fatty acid esters; wherein the weight ratio of melphalan to polyoxyethylene sorbitan fatty acid esters is f...

Ready To Use Dantrolene Compositions

The present invention relates to a stable, multidose, ready to use, non-aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof; (ii) non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aq...

Stable Inhalation Compositions Of Indacaterol

The present invention relates to stable long acting inhalation composition comprising indacaterol or its acceptable salts at a concentration from about 15 mcg/mL up to about 150 mcg/mL, and optionally comprising one or more anticholinergic agent. It also relates to use of such compositions for the prevention and/or ...

Process For The Preparation Of Paclitaxel Nanoparticles

The present invention relates to a method for inhibiting the growth of the paclitaxel droplet size in a homogenized emulsion, during the preparation of paclitaxel nanoparticle, by diluting the homogenized emulsion with water or aqueous media within 30 minutes of homogenized emulsion formation. The invention also rel...

Vitamin K1 Injection Device Kit

The present invention relates to a simple, convenient, user-friendly, ready to administer pre-filled syringe injection device, for delivery of medication composition used for the prophylaxis and treatment of vitamin K deficiency bleeding in the neonates and other age groups.

Pharmaceutical Composition Of Lifitegrast And Loteprednol Etabonate

The present invention relates to pharmaceutical composition comprising combination of Lifitegrast and Loteprednol etabonate along with one or more pharmaceutically acceptable excipients for the treatment of dry eye disease.

“Stable Pharmaceutical Compositions Of Hydrocortisone Or Combinations Thereof”

ABSTRACT “STABLE PHARMACEUTICAL COMPOSITIONS OF HYDROCORTISONE OR COMBINATIONS THEREOF” The present invention relates to a stable pharmaceutical composition of corticosteroid and optionally other active agent(s). The present invention relates to a stable pharmaceutical composition of hydrocortisone and optiona...

"Stable Injectable Compositions Of Glp 2 Peptide"

The present invention relates to a stable GLP-2 peptide injectable composition, comprising GLP-2 peptide agent comprises of sodium; wherein the GLP-2 peptide agent is teduglutide or h[Gly2]GLP-2 and one or more pharmaceutically acceptable excipient(s).

Charges

96 Crore
14 February 2017
Kotak Mahindra Bank Limited
89 Crore
20 October 2015
State Bank Of Bikaner & Jaipur
12 Crore
07 March 2011
State Bank Of India
2 Crore
09 September 2020
Kotak Mahindra Bank Limited
5 Crore
12 March 2021
Kotak Mahindra Bank Limited
1 Crore
20 April 2023
Others
0
24 November 2022
Others
0
24 November 2022
Others
0
26 August 2022
Others
0
23 August 2021
Others
0
23 August 2021
Others
0
14 February 2017
Others
0
19 August 2021
Others
0
12 March 2021
Others
0
09 September 2020
Others
0
07 March 2011
State Bank Of India
0
20 October 2015
State Bank Of Bikaner & Jaipur
0
20 April 2023
Others
0
24 November 2022
Others
0
24 November 2022
Others
0
26 August 2022
Others
0
23 August 2021
Others
0
23 August 2021
Others
0
14 February 2017
Others
0
19 August 2021
Others
0
12 March 2021
Others
0
09 September 2020
Others
0
07 March 2011
State Bank Of India
0
20 October 2015
State Bank Of Bikaner & Jaipur
0
20 April 2023
Others
0
24 November 2022
Others
0
24 November 2022
Others
0
26 August 2022
Others
0
23 August 2021
Others
0
23 August 2021
Others
0
14 February 2017
Others
0
19 August 2021
Others
0
12 March 2021
Others
0
09 September 2020
Others
0
07 March 2011
State Bank Of India
0
20 October 2015
State Bank Of Bikaner & Jaipur
0